By Suherman Candra Maholtra 
Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have announced a significant breakthrough in the fight against tuberculosis (TB) with the development of an experimental therapeutic DNA vaccine delivered intranasally. This novel vaccine is specifically engineered to bolster the immune system’s ability to identify and eliminate "persisters"—subsets of drug-tolerant TB bacteria that frequently survive standard antibiotic courses and lead to disease relapse. The study, published in the Journal of Clinical Investigation, offers a potential paradigm shift in how the world’s leading infectious killer is managed, moving toward a combined approach of immunotherapy and pharmacology.
The Global Burden of Tuberculosis and the "Persister" Problem
Tuberculosis remains a formidable adversary for global health, having plagued human populations for more than 6,000 years. Despite the availability of antibiotics since the mid-20th century, TB continues to claim more lives annually than any other single infectious pathogen, with the exception of the COVID-19 pandemic’s peak years. According to recent data from the World Health Organization (WHO), the scale of the crisis is immense: approximately 2 billion people, or one-quarter of the global population, carry latent TB infections. While these individuals do not show symptoms, they serve as a reservoir for future outbreaks.
In 2024 alone, over 10 million people developed active TB, resulting in 1.2 million deaths. One of the primary obstacles to eradicating the disease is the lengthy and arduous nature of the treatment. Standard TB regimens require patients to take multiple antibiotics for six to nine months. The complexity of these treatments often leads to poor compliance, which in turn fuels the rise of multidrug-resistant TB (MDR-TB).
The biological root of this lengthy treatment requirement lies in "persisters." Unlike drug-resistant bacteria, which possess genetic mutations that render antibiotics ineffective, persisters are genetically susceptible but enter a state of metabolic dormancy. In this "sleep" state, they become tolerant to drugs that typically target actively dividing cells. Once the treatment ends, these dormant bacteria can "wake up," causing a relapse and requiring further, often more toxic, medical intervention.
A Novel Genetic Approach: The relMtb and Mip3α Fusion
The experimental vaccine developed by the Johns Hopkins team utilizes a sophisticated genetic strategy to bridge the gap between the innate and adaptive immune systems. The vaccine combines two specific genes: relMtb and Mip3α.
The relMtb gene is a critical component of the TB bacterium’s survival kit. It produces the RelMtb protein, which acts as a master regulator, allowing the microbe to survive hostile environments characterized by low oxygen, nutrient scarcity, and the presence of antibiotics. By targeting this specific protein, the vaccine aims to strip away the bacterium’s primary defense mechanism against the host’s immune system and medical treatments.
To ensure the immune system notices this target, the researchers fused relMtb with the Mip3α gene. This fusion creates a molecular "flare" that attracts immature dendritic cells. Dendritic cells are the sentinels of the immune system; their role is to ingest foreign proteins and "present" them to T cells, which then coordinate a massive, targeted attack.
"Fusing relMtb with the Mip3α gene produces a signal that attracts immature dendritic cells—key cells that pick up TB proteins and ‘present’ them to T cells," explained Dr. Styliani Karanika, the study’s lead author and assistant professor of medicine at the Johns Hopkins University School of Medicine. This dual-gene approach ensures that the immune system is not only alerted to the presence of the bacteria but is specifically trained to recognize the proteins associated with the most stubborn, dormant forms of the disease.
The Strategic Advantage of Intranasal Delivery
A distinctive feature of the new vaccine is its delivery method. While most vaccines are administered via intramuscular injection, the Johns Hopkins team opted for an intranasal route. This decision is rooted in the biology of TB infection, which primarily targets the respiratory system.
By delivering the DNA vaccine through the nose, the researchers are able to stimulate the respiratory mucosa directly. This localized approach generates T-cell immunity within the airways and lung tissue—the exact site where TB bacteria first establish an infection. This "front-line" defense is supplemented by a systemic immune response that circulates through the bloodstream, providing a comprehensive, two-tiered layer of protection.
"Intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs, helping generate long-lasting localized T-cell immunity in the airways and lungs," noted Dr. Karanika. This localized focus is believed to be essential for preventing the initial colonization and subsequent persistence of the bacteria.
Evidence of Efficacy: Mouse and Primate Studies
The research team conducted extensive testing to validate the vaccine’s efficacy, beginning with murine (mouse) models. The results were highly encouraging. When administered alongside first-line TB drug therapy, the intranasal DNA vaccine significantly accelerated the clearance of the bacteria. Mice receiving the vaccine showed reduced lung inflammation and, crucially, a marked decrease in relapse rates after the antibiotic treatment was discontinued.
Furthermore, the vaccine demonstrated a synergistic effect with the "BPaL" regimen—a potent combination of bedaquiline, pretomanid, and linezolid used to treat highly drug-resistant TB. The vaccine helped these powerful drugs work more efficiently, suggesting that immunotherapy could become a vital tool in managing the most difficult-to-treat cases of MDR-TB.
Following the success in mice, the team moved to rhesus macaques, whose immune systems more closely mirror those of humans. In these primates, the vaccine successfully triggered measurable TB-specific immune responses in both the blood and the airways. These responses included the activation of both CD4 (helper) and CD8 (killer) T cells.
Importantly, the immune activity in the primates lasted for at least six months. This longevity suggests that the vaccine could provide durable protection, a necessary requirement for any therapeutic intervention intended for global use. While the primate study focused on immune activation rather than direct challenge with TB infection, the markers observed were consistent with the protective responses seen in the mouse efficacy trials.
Chronology of Development and Future Research
The development of this vaccine follows years of research at the Johns Hopkins Center for Tuberculosis Research, focusing on the metabolic pathways of Mycobacterium tuberculosis. The identification of the relMtb gene as a vulnerability in the bacterium’s "persistence" strategy was a pivotal moment that led to the current DNA vaccine design.
The progression from laboratory bench to animal models represents a significant timeline of innovation:
- Identification of Persister Genes: Researchers identified relMtb as a key factor in antibiotic tolerance.
- Vaccine Design: The fusion of relMtb with Mip3α was engineered to enhance antigen presentation.
- Mouse Efficacy Trials: Tests confirmed faster bacterial clearance and reduced relapse when paired with antibiotics.
- Non-human Primate Studies: Validation of the vaccine’s ability to stimulate complex immune systems and provide durable responses.
Despite these successes, the researchers emphasize that more work is needed. The next steps involve further preclinical safety testing and the optimization of the DNA delivery platform before human clinical trials can begin. These future trials will be essential to determine if the immune responses seen in primates translate into clinical protection for humans.
Analysis of Implications for Global Health Policy
The potential impact of a successful therapeutic TB vaccine is immense. For decades, the global strategy for TB control has relied almost exclusively on improving antibiotic access and diagnostics. However, the plateauing of mortality rates and the rise of drug resistance suggest that antibiotics alone may not be enough to end the epidemic.
The WHO has recently called for the development of therapeutic vaccines that can complement existing treatments. If the Johns Hopkins vaccine proves successful in humans, it could:
- Shorten Treatment Duration: By helping the immune system kill "persisters" that antibiotics miss, the vaccine could reduce the standard treatment time from months to weeks.
- Prevent Relapse: Reducing the "dormant reservoir" of bacteria would significantly lower the rates of disease recurrence, which is a major driver of TB transmission.
- Combat Drug Resistance: By making existing drugs like the BPaL regimen more effective, the vaccine provides a new weapon against strains that are currently nearly untreatable.
- Economic Stability: DNA vaccines are generally more stable and cheaper to produce than protein-based vaccines, making them ideal for use in low- and middle-income countries where the TB burden is highest.
Research Support and Collaborations
The study was a collaborative effort involving a large team of scientists from Johns Hopkins, including experts in infectious diseases, immunology, and public health. Lead author Styliani Karanika was joined by senior researchers including Petros Karakousis, Richard Markham, and Eric Nuermberger.
The research was supported by extensive federal funding from the National Institutes of Health (NIH), including various grants from the National Institute of Allergy and Infectious Diseases (NIAID). Additional support was provided by the Gilead HIV Research Scholar Award, the Johns Hopkins University Tuberculosis Research Advancement Center, and the Potts Memorial Foundation.
Inventors Karanika, Gordy, Markham, and Karakousis have filed a patent (PCT/US2023/065584) for the Mip3α/relMtb vaccine, signaling the transition of this technology from a laboratory discovery toward a viable medical product.
As the global medical community looks toward the 2030 goal of ending the TB epidemic, the development of the Mip3α/relMtb vaccine represents a critical "translational bridge." It moves the field closer to a future where the world’s oldest infectious enemy can finally be defeated through a combination of precision medicine and the revitalized power of the human immune system.
